Clinical characteristics and sequence complexity of anaplastic lymphoma kinase gene fusions in Chinese lung cancer patients

Morris, 1994, Fusion of a kinase gene ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma, Science, 263, 1281, 10.1126/science.8122112 Soda, 2007, Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer, Nature, 448, 561, 10.1038/nature05945 Shaw, 2013, Crizotinib versus chemotherapy in advanced ALK-positive lung cancer, N. Eng. J. Med., 368, 2385, 10.1056/NEJMoa1214886 Solomon, 2014, First-line crizotinib versus chemotherapy in ALK-positive lung cancer, N. Eng. J. Med., 371, 2167, 10.1056/NEJMoa1408440 Takeuchi, 2009, KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer, Clin. Cancer Res., 15, 3143, 10.1158/1078-0432.CCR-08-3248 Togashi, 2012, KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only, PLoS One, 7, e31323, 10.1371/journal.pone.0031323 Takeuchi, 2008, Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts, Clin. Cancer Res., 14, 6618, 10.1158/1078-0432.CCR-08-1018 Yang, 2012, Gene fusions in non-small-cell lung cancer, Lung Cancer Manage., 1, 283, 10.2217/lmt.12.41 Penzel, 2012, A novel EML4-ALK variant: exon 6 of EML4 fused to exon 19 of ALK, J. Thorac. Oncol., 7, 1198, 10.1097/JTO.0b013e3182598af3 Wang, 2012, The use of quantitative real-time reverse transcriptase PCR for 5' and 3' portions of ALK transcripts to detect ALK rearrangements in lung cancers, Clin. Cancer Res., 18, 4725, 10.1158/1078-0432.CCR-12-0677 Lee, 2015, Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: a meta-analysis, J. Clin. Oncol., 33, 1958, 10.1200/JCO.2014.58.1736 Yang, 2015, Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised phase 3 trials, Lancet Oncol., 16, 141, 10.1016/S1470-2045(14)71173-8 Zhang, 2010, Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression, Mol. Cancer, 9, 188, 10.1186/1476-4598-9-188 Jiang, 2008, EGFR genetic heterogeneity of non-small cell lung cancers contributing to acquired gefitinib resistance, Int. J. Cancer, 123, 2480, 10.1002/ijc.23868 Kwak, 2010, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer, N. Eng. J. Med., 363, 1693, 10.1056/NEJMoa1006448 Zhou, 2011, East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians, Chin. J. Cancer, 30, 287, 10.5732/cjc.011.10106 Bollig-Fischer, 2015, Racial diversity of actionable mutations in non-small cell lung cancer, J. Thorac. Oncol., 10, 250, 10.1097/JTO.0000000000000420 Rodig, 2009, Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population, Clin. Cancer Res., 15, 5216, 10.1158/1078-0432.CCR-09-0802 Abdelraouf, 2015, Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practice, BMC Res. Notes, 8, 688, 10.1186/s13104-015-1675-x Hong, 2014, A large-scale cross-sectional study of ALK rearrangements and EGFR mutations in non-small-cell lung cancer in Chinese Han population, Sci. Rep., 4, 7268, 10.1038/srep07268 Li, 2013, Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer, PLoS One, 8, e52093, 10.1371/journal.pone.0052093 Shaw, 2009, Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK, J. Clin. Oncol., 27, 4247, 10.1200/JCO.2009.22.6993 Lee, 2012, Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation, Lung Cancer, 77, 460, 10.1016/j.lungcan.2012.04.012 Yang, 2014, Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation, Clin. Cancer Res., 20, 1383, 10.1158/1078-0432.CCR-13-0699 Won, 2015, Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor, Ann. Oncol., 26, 348, 10.1093/annonc/mdu530 Hu, 2017, Concurrent gene alterations with EGFR mutation and treatment efficacy of EGFR-TKIs in Chinese patients with non-small cell lung cancer, Oncotarget, 8, 25046, 10.18632/oncotarget.15337 Wen, 2016, Detection of EML4-ALK fusion gene and features associated with EGFR mutations in Chinese patients with non-small-cell lung cancer, Onco Targets Ther., 9, 1989, 10.2147/OTT.S100303 Lei, 2016, Anaplastic lymphoma kinase variants and the percentage of ALK-positive tumor cells and the efficacy of crizotinib in advanced NSCLC, Clin. Lung Cancer, 17, 223, 10.1016/j.cllc.2015.09.002 Heuckmann, 2012, Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants, Clin. Cancer Res., 18, 4682, 10.1158/1078-0432.CCR-11-3260 Woo, 2017, Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer, Ann. Oncol., 28, 791, 10.1093/annonc/mdw693 Yoshida, 2016, Differential crizotinib response duration among ALK Fusion variants in ALK-positive non-small-cell lung cancer, J. Clin. Oncol., 34, 3383, 10.1200/JCO.2015.65.8732 Tu, 2017, A story of ALK variants and the efficacy of ALK inhibitors: moving toward precision oncology, Trans. Cancer Res., 6, S292, 10.21037/tcr.2017.03.07 Ali, 2016, Comprehensive genomic profiling identifies a subset of crizotinib-responsive ALK-rearranged non-small cell lung cancer not detected by fluorescence in situ hybridization, Oncologist, 21, 762, 10.1634/theoncologist.2015-0497 To, 2013, Detection of ALK rearrangement by immunohistochemistry in lung adenocarcinoma and the identification of a novel EML4-ALK variant, J. Thorac. Oncol., 8, 883, 10.1097/JTO.0b013e3182904e22 Wang, 2015, EML4-ALK fusion detected by RT-PCR confers similar response to crizotinib as detected by FISH in patients with advanced non-small-cell lung cancer, J. Thorac. Oncol., 10, 1546, 10.1097/JTO.0000000000000668